MDXG Earnings Date: Feb 24, 2027 (Estimated) — MiMedx Group, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MDXG's next earnings date?
MiMedx Group, Inc. (MDXG) is expected to report Q4 2026 earnings on Wednesday, February 24, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.03 on revenue of $76.8M.
How did MDXG do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), MiMedx Group, Inc. posted EPS of -$0.01 versus the $0.00 estimate, a miss of 3671.4%. Revenue was $62.3M against a $68.6M estimate. The stock's 1-day post-earnings move was +0.5%.
How much does MDXG stock move after earnings?
MDXG beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.0% (up or down) in the day after earnings.
About MiMedx Group, Inc.
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
🤖 AI Earnings Analysis
MiMedx’s $25 million wound-care patent license and favorable federal ruling bolster its competitive position, but results were weak: revenue fell 46% year over year to $62 million, missing estimates despite surgical-volume growth.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 0.00 | -0.01 | -3671.43% | $62.3M | ❌ Miss | +0.51% | — | — |
| 2026-07-29 | Q2 2026 | -0.03 | -0.05 | -66.67% | $64.4M | ❌ Miss | +0.95% | -1.65% | +6.62% |
| 2026-04-29 | Q1 2026 | -0.04 | -0.05 | -25.00% | $59.0M | ❌ Miss | +8.91% | +18.64% | +19.29% |
| 2026-02-25 | Q4 2025 | 0.10 | 0.14 | +40.00% | $118.1M | ✅ Beat | -6.44% | -8.71% | -25.38% |
| 2025-10-29 | Q3 2025 | 0.07 | 0.15 | +114.29% | $113.7M | ✅ Beat | +2.92% | +10.71% | -4.31% |
| 2025-07-30 | Q2 2025 | 0.06 | 0.10 | +66.67% | $98.6M | ✅ Beat | +10.28% | +11.04% | +10.12% |
| 2025-04-30 | Q1 2025 | 0.05 | 0.06 | +20.00% | $88.2M | ✅ Beat | -8.14% | +1.45% | -6.54% |
| 2025-02-26 | Q4 2024 | 0.08 | 0.07 | -12.50% | $92.9M | ❌ Miss | +1.62% | +0.94% | -3.37% |
Showing last 8 quarters.